Post-trial follow-up | OS with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma.
25 Nov, 2022 | 12:25h | UTCOriginal Study: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine